Anke Bio Announces Global Commercialization Strategy for CD7-CAR-T Therapy via Licensing and Partnerships

Gelonghux 11/20 | ANKEBIO stated on the interactive platform that after the approval of Bo sheng ji's CD7-CAR-T product, there are plans to attempt direct registration for marketing in Belt and Road countries. As for Europe and the United States, Bo sheng ji has communicated with the U.S. Food and Drug Administration (FDA) and may use clinical data from China to directly apply for Phase II clinical trials in the U.S., which will be conducted by partners in the U.S. In terms of business development, it may proceed through external licensing or collaborative development.